DAVENPORT & Co LLC Grows Position in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)

DAVENPORT & Co LLC raised its stake in shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) by 12.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 771,189 shares of the company’s stock after purchasing an additional 83,403 shares during the quarter. DAVENPORT & Co LLC owned about 24.10% of ALPS Medical Breakthroughs ETF worth $27,461,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in SBIO. Central Valley Advisors LLC purchased a new position in shares of ALPS Medical Breakthroughs ETF during the first quarter worth $200,000. McGuire Investment Group LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at about $244,000. Griffin Asset Management Inc. purchased a new stake in shares of ALPS Medical Breakthroughs ETF in the fourth quarter worth about $262,000. Phoenix Wealth Advisors grew its holdings in ALPS Medical Breakthroughs ETF by 11.5% during the fourth quarter. Phoenix Wealth Advisors now owns 10,938 shares of the company’s stock worth $359,000 after acquiring an additional 1,130 shares during the period. Finally, Virtu Financial LLC purchased a new position in ALPS Medical Breakthroughs ETF during the fourth quarter valued at approximately $518,000.

ALPS Medical Breakthroughs ETF Trading Up 4.7 %

Shares of ALPS Medical Breakthroughs ETF stock traded up $1.63 during trading hours on Thursday, reaching $36.54. The stock had a trading volume of 2,648 shares, compared to its average volume of 12,667. ALPS Medical Breakthroughs ETF has a twelve month low of $23.21 and a twelve month high of $38.80. The stock’s 50 day moving average is $33.65 and its 200 day moving average is $33.98.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.